JMD GMP oligos for in vitro Diagnostics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/jmoldx.2009.080138 on December 4, 2008

Published online before print December 4, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmoldx.2009.080138v1
11/1/12    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaludercic, N.
Right arrow Articles by Paolocci, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaludercic, N.
Right arrow Articles by Paolocci, N.
Journal of Molecular Diagnostics 2009, Vol. 11, No. 1
Copyright © 2009 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2009.080138

Commentary

Genes, Geography and Geometry

The "Critical Mass" in Hypertrophic Cardiomyopathy

Nina Kaludercic*, Carlo Reggiani{dagger} and Nazareno Paolocci*{ddagger}

From the Division of Cardiology, * Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland; the Department of Human Anatomy and Physiology, {dagger} University of Padova, Padova, Italy; and the Department of Clinical Medicine, {ddagger} Section of General Pathology, University of Perugia, Perugia, Italy

Abstract

This Commentary discusses the potential of angiotensin II type 1 receptor blockade as a treatment option for patients with hypertrophic cardiomyopathy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology and the Association for Molecular Pathology.